ClinicalTrials.gg
RecruitingNCT06377852Updated Nov 2, 2026

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

A Phase 3 interventional study of Palbociclib 125mg and Ribociclib 600mg in Metastatic Breast Cancer, sponsored by American Society of Clinical Oncology. Recruiting at 92 sites in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by American Society of Clinical Oncology · Phase 3, Interventional, and Treatment

How we know · 6 judgments

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years later.
Updated Nov 2, 202619 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 111 studies testing palbociclib in Breast Neoplasms — 19 open to participants now, 43 under way, 9 of them phase 3. palbociclib · Breast Neoplasms.

Planned enrollment
12th of 111
500 · median 100
Started
2024
with 5 others
Phase 3
20 of 111
4 open now
Primary completion
2028-08
later than 37 of 42 live
Registered
101st of 111
by date

Among the 111 studies testing palbociclib in Breast Neoplasms, this one is the 12th largest by planned enrollment, is one of 6 that started in 2024, is one of 20 in phase 3, reaches primary completion later than 37 of the 42 other live ones, and was the 101st registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

19 of the 111 studies testing palbociclib in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About palbociclib

palbociclib: first FDA approval 2015 (IBRANCE), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies testing palbociclib in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to generate evidence on an alternative dosing strategy for CDK4/6 inhibitors to help more patients with Metastatic Breast Cancer (MBC) (age ≥ 60 years) tolerate side effects and stay on treatment longer, to derive the most clinical benefit from these drugs.

The primary objective of the CDK Study is to compare time to treatment discontinuation (TTD) on the approved dosing for palbociclib (125 mg orally daily on days 1-21 of 28-day cycle) or ribociclib (600 mg orally daily on days 1-21 of 28-day cycle) vs. TTD using titrated dosing approach with the same schedule but starting at a lower dose of palbociclib (100 mg or 75 mg) or ribociclib (400 mg or 200 mg) and escalating the dose if well-tolerated in combination with provider/patient choice endocrine therapy (aromatase inhibitor (AI) or fulvestrant) in patients age 60 or older with HR+/HER2- MBC. The secondary and exploratory objectives will generate evidence needed to personalize treatment decisions by comparing patient-centric secondary outcomes and evaluating baseline factors.

Together with their treating physician, participants will choose the CDK4/6 inhibitor (palbociclib or ribociclib) and which endocrine therapy (aromatase inhibitor or fulvestrant) of their choice but will be randomized to either Arm 1 (indicated dosing) or Arm 2 (titrated dosing).

Note: Telehealth visits are allowed at any time per institutional guidelines. In addition, the study allows for remote consenting per institutional guidelines.

Read the detailed description

The CDK4/6 Inhibitor Dosing Knowledge Study (CDK Study) will study CDK4/6 inhibitor dosing regimens in patients 60 or older with Metastatic Breast Cancer (MBC). The overarching goal of this pragmatic, randomized trial is to compare an "indicated" dosing approach, as listed on the FDA-approved drug label, that starts at the full dose of a CDK4/6 inhibitor (palbociclib or ribociclib) with dose reduction based on tolerability versus a "titrated" dosing approach that starts at a lower dose of a CDK4/6 inhibitor and then titrates up to full dose as tolerated. CDK4/6 inhibitors will be given in combination with endocrine therapy (either an aromatase inhibitor (AI) or fulvestrant) based on the choice of the treating clinician.

The primary endpoint will be time to treatment discontinuation (TTD), defined as the time from randomization to last dose of the CDK4/6 inhibitor. The hypothesis is that starting low and escalating as tolerated will help older patients (> 60 years) stay on therapy longer. Eligibility criteria are broad to allow patients who are not typically included in clinical trials to participate, allowing for a more representative sample of participants. The investigators will conduct sub-group analyses based on age (60-64 years vs. 65-74 years vs. ≥75 years) and baseline frailty scores. This study builds upon the lessons learned from prior studies with CDK4/6 inhibitors. The investigators will augment the standard assessment of treatment toxicities assessed by the health care team with prospectively collected patient-reported outcomes data to better reflect how participants tolerate the different dosing approaches.

03

Conditions studied

  • Metastatic Breast Cancer

Browse trials for

Keywords

  • MBC
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Hormone receptor positive (HR+) negative breast cancer. Cut-off values for positive/negative staining should be as per standard practice in accordance with ASCO/CAP (American Society of Clinical Oncology/College of American Pathologists) guidelines. Verification of histology is preferred at the time of recurrence and where not possible or necessary in the judgment of the treating physician, the study will accept histology from the initial diagnosis.
  2. Candidate for planned endocrine therapy in combination with 1st use of palbociclib or ribociclib, in the metastatic setting. The planned endocrine partner can be an aromatase inhibitor (letrozole, anastrozole, exemestane) or fulvestrant, selected through patient/provider choice.
  3. Aged 60 years or older
  4. Adequate bone marrow and organ function. Laboratory values must be within normal institutional limits, or within ranges as indicated below, or demonstrate minor abnormalities that are deemed clinically non-significant by the investigator.

    • ≥ 1,000/µL
    • Total ≤ 1.5 x institutional (ULN) (participants with documented Gilbert's disease are allowed total bilirubin up to 5X ULN)
    • (SGOT)/ALT (SGPT) \<3 x institutional ULN, or ≤ 5 x ULN for subjects with documented metastatic disease to the liver.
  5. Baseline ≤ 480 ms (only for ribociclib patients)
  6. Ability to understand and the willingness to provide . Note: Remote consent is allowed per institutional guidelines.

Exclusion criteria

Exclusion Criteria:

  1. Previous treatment with a CDK4/6 inhibitor for breast cancer, or previous treatment within the past 12 months with a CDK4/6 inhibitor in the neo/ breast cancer setting.
  2. Received greater than 60 days (in the metastatic setting) of the specific endocrine therapy agent planned as partner to the CDK4/6 inhibitor in the study at the time of randomization.
  3. Known history of intolerance or allergy to the planned agents used in this trial.
  4. Uncontrolled intercurrent illness that, as evaluated by the treating clinician, would hinder compliance with study requirements.
  5. Concurrent therapy with other agents or anticancer therapy beyond aromatase inhibitors or fulvestrant. Note: radiation is allowed at any time.
  6. Rapidly progressive . Note: only applies to patients with known brain metastases. Brain imaging not required for enrollment.
  7. Active or chronic or C are eligible provided they meet liver function laboratory criteria and are not on medication with a known interaction with the study agents.
  8. Current use of drugs that have known potential to prolong the (e.g., antiarrhythmic drugs), for patients on ribociclib. Note: If concomitant use cannot be avoided, monitor when initiating, during concomitant use, and as clinically indicated. Refer to crediblemeds.org as a resource.
  9. Prior or concurrent that are undergoing active treatment.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    Arm 1: Indicated Dose

    Arm 1 of the study is the indicated dosing regimen, provided in the FDA approved drug label: participants will start cycle 1 with either 125mg dose of palbociclib or 600mg dose of ribociclib, in combination with endocrine therapy (AI or fulvestrant).

    Drug: Palbociclib 125mg · Drug: Ribociclib 600mg

  • Experimental
    Arm 2: Titrated Dose

    Arm 2 is the titrated dosing regimen: participants will start cycle 1 with either 100 mg or 75 mg dose of palbociclib or 400 mg or 200 mg dose of ribociclib, in combination with endocrine therapy (AI or fulvestrant). For cycle 2 and for subsequent cycles, escalation to the indicated dose will be based on treatment tolerance.

    Drug: Ribociclib · Drug: Palbociclib

Interventions

  • DrugPalbociclibStudies of PalbociclibPalbociclib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Arm 1: Indicated dosing for palbociclib (125 mg orally daily on days 1-21 of 28-day cycle)

  • DrugRibociclibStudies of RibociclibRibociclib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Arm 1: Indicated dosing of ribociclib (600 mg orally daily on days 1-21 of 28-day cycle)

  • Arm 2: Titrated dosing approach with the same schedule but starting at a lower dose of ribociclib (400 mg or 200 mg) and escalating the dose if well-tolerated in combination with provider/patient choice of endocrine therapy.

  • Arm 2: Titrated dosing approach with the same schedule but starting at a lower dose of palbociclib (100 mg or 75 mg) and escalating the dose if well-tolerated in combination with provider/patient choice of endocrine therapy.

This study also gives FulvestrantStudies of FulvestrantFulvestrant pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Time to Treatment Discontinuation (TTD)

    Our primary outcome is time to CDK4/6 inhibitor discontinuation (TTD): the number of days between randomization and the last day the patient takes any dose of the same CDK4/6 inhibitor (regardless of drug holds, dose changes

    Time frame: up to 48 months

Secondary outcomes

  1. Toxicity (grade 3-4 AEs)

    Assessed in each arm of the study and study drug

    Time frame: up to 48 months

  2. Event-Free survival (EFS)

    Assessed in each arm of the study and study drug

    Time frame: up to 48 months

  3. Quality of life assessed by patient reported outcomes

    PROMIS-29 (3 domains of 12 questions, physical function, fatigue, participation in social activities), FACT-G Item GP5 (1 question)

    Time frame: up to 48 months

  4. Time to dose reduction and escalation

    For titrated arm. Assessed in each arm of the study and study drug

    Time frame: up to 48 months

  5. Reason for not escalating

    Assessed in each arm of the study and study drug

    Time frame: up to 48 months

  6. Treatment received (missed doses, cumulative dose, etc.)

    Assessed in each arm of the study and study drug

    Time frame: up to 48 months

  7. Healthcare utilization (ED visits, hospital admissions, etc.)

    ED visits, hospital admissions, etc., assessed in each arm of the study and study drug

    Time frame: up to 48 months

  8. Body Mass Index

    weight and height will be combined to report BMI in kg/m\^2

    Time frame: up to 48 months

07

Study locations

92 of 92 sites recruiting
  • Ironwood Cancer & Research Centers
    Chandler, Arizona 85224, United States
    Recruiting
  • Ironwood Cancer & Research Centers
    Gilbert, Arizona 85297, United States
    Recruiting
  • Ironwood Cancer & Research Centers
    Glendale, Arizona 85306, United States
    Recruiting
  • Ironwood Cancer & Research Centers
    Goodyear, Arizona 85395, United States
    Recruiting
  • Ironwood Cancer & Research Centers
    Mesa, Arizona 85202, United States
    Recruiting
  • Ironwood Cancer & Research Centers
    Mesa, Arizona 85206, United States
    Recruiting
  • Ironwood Cancer & Research Centers
    Phoenix, Arizona 85028, United States
    Recruiting
  • Ironwood Cancer & Research Centers
    Scottsdale, Arizona 85260, United States
    Recruiting
  • Providence Medical Foundation
    Eureka, California 95501, United States
    Recruiting
  • Providence Medical Foundation
    Santa Rosa, California 95403, United States
    Recruiting
  • University of Colorado Anschutz Medical Campus
    Aurora, Colorado 80045, United States
    Recruiting
  • UCHealth Cherry Creek Medical Center
    Denver, Colorado 80206, United States
    Recruiting
  • UCHealth Highlands Ranch Hospital
    Highlands Ranch, Colorado 80129, United States
    Recruiting
  • Smilow Cancer Hospital Care Center - Derby
    Derby, Connecticut 06418, United States
    Recruiting
    • Carl Brown · Contactcarl.brown@yale.edu · 475-241-1065
    • Maryam Lustberg, MD · Principal investigator
  • Smilow Cancer Hospital Care Center - Fairfield
    Fairfield, Connecticut 06824, United States
    Recruiting
    • Carl Brown · Contactcarl.brown@yale.edu · 475-241-1065
    • Maryam Lustberg, MD · Principal investigator
  • Smilow Cancer Hospital at Glastonbury
    Glastonbury, Connecticut 06033, United States
    Recruiting
    • Carl Brown · Contactcarl.brown@yale.edu · 475-241-1065
    • Maryam Lustberg, MD · Principal investigator
  • Smilow Cancer Hospital Care Center - Greenwich
    Greenwich, Connecticut 06830, United States
    Recruiting
    • Carl Brown · Contactcarl.brown@yale.edu · 475-241-1065
    • Maryam Lustberg, MD · Principal investigator
  • Smilow Cancer Hospital Care Center - Guilford
    Guilford, Connecticut 06437, United States
    Recruiting
    • Carl Brown · Contactcarl.brown@yale.edu · 475-241-1065
    • Maryam Lustberg, MD · Principal investigator
  • Smilow Cancer Hospital at Saint Francis
    Hartford, Connecticut 06105, United States
    Recruiting
    • Carl Brown · Contactcarl.brown@yale.edu · 475-241-1065
    • Maryam Lustberg, MD · Principal investigator
  • Smilow Cancer Hospital - Yale New Haven Health
    New Haven, Connecticut 06510, United States
    Recruiting
    • Carl Brown · Contactcarl.brown@yale.edu · 475-241-1065
    • Maryam Lustberg, MD, MPH · Principal investigator
  • Yale University/Yale Cancer Center/Yale School of Medicine
    New Haven, Connecticut 06510, United States
    Recruiting
    • Carl Brown · Contactcarl.brown@yale.edu · 475-241-1065
    • Maryam Lustberg, MD · Principal investigator
  • Smilow Cancer Hospital Care Center - North Haven
    North Haven, Connecticut 06473, United States
    Recruiting
    • Carl Brown · Contactcarl.brown@yale.edu · 475-241-1065
    • Maryam Lustberg, MD · Principal investigator
  • Smilow Cancer Hospital Care Center - Torrington
    Torrington, Connecticut 06790, United States
    Recruiting
    • Carl Brown · Contactcarl.brown@yale.edu · 475-241-1065
    • Maryam Lustberg, MD · Principal investigator
  • Smilow Cancer Hospital Care Center - Trumbull
    Trumbull, Connecticut 06611, United States
    Recruiting
    • Carl Brown · Contactcarl.brown@yale.edu · 475-241-1065
    • Maryam Lustberg, MD · Principal investigator
  • Smilow Cancer Hospital Care Center - Waterbury
    Waterbury, Connecticut 06708, United States
    Recruiting
    • Carl Brown · Contactcarl.brown@yale.edu · 475-241-1065
    • Maryam Lustberg · Principal investigator
  • Smilow Cancer Hospital - Waterford
    Waterford, Connecticut 06385, United States
    Recruiting
    • Carl Brown · Contactcarl.brown@yale.edu · 475-241-1065
    • Maryam Lustberg, MD · Principal investigator
  • Miami Cancer Institute
    Miami, Florida 33176, United States
    Recruiting
  • Miami Cancer Institute
    Plantation, Florida 33324, United States
    Recruiting
  • Emory University Winship Cancer Institute
    Atlanta, Georgia 30322, United States
    Recruiting
  • Liberty County Cancer Care
    Hinesville, Georgia 31313, United States
    Recruiting
    • Stephanie Reyes · Contactsmiths1@sjchs.org · 912-819-5723
    • Leonard Henry, MD · Principal investigator
  • Pembroke Medical Oncology & St Joseph's/Candler Oncology Infusion Suite
    Pembroke, Georgia 31321, United States
    Recruiting
    • Stephanie Reyes · Contactsmiths1@sjchs.org · 912-819-5723
    • Leonard Henry, MD · Principal investigator
  • Lewis Cancer and Research Pavilion
    Savannah, Georgia 31405, United States
    Recruiting
    • Stephanie Reyes · Contactsmiths1@sjchs.org · 912-819-5723
    • Leonard Henry, MD · Principal investigator
  • Candler Medical Oncology Practice and Infusion
    Statesboro, Georgia 30458, United States
    Recruiting
    • Stephanie Reyes · Contactsmiths1@sjchs.org · 912-819-5723
    • Leonard Henry, MD · Principal investigator
  • Northwest Cancer Center
    Crown Point, Indiana 46307, United States
    Recruiting
  • Northwest Cancer Center-Dyer
    Dyer, Indiana 46311, United States
    Recruiting
  • St. Mary Medical Center
    Hobart, Indiana 46342, United States
    Recruiting
  • Powers Health Cancer Research Foundation
    Munster, Indiana 46321, United States
    Recruiting
  • Northwest Cancer Center
    Valparaiso, Indiana 46383, United States
    Recruiting
  • The University of Kansas Cancer Center
    Westwood, Kansas 66205, United States
    Recruiting
    • call or email to be connected · ContactCTNurseNav@kumc.edu · 913-945-7552
    • Ryan Rader, MD · Principal investigator
  • The Jackson Laboratory (JAX) - Harold Alfond Center for Cancer Care
    Augusta, Maine 04330, United States
    Recruiting
  • The Jackson Laboratory (JAX) - Northern Light Cancer Care
    Brewer, Maine 04412, United States
    Recruiting
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
    Recruiting
    • Call · Contact877-338-7425
    • Erica Mayer, MD · Principal investigator
  • Dana-Farber Brigham Cancer Center Foxborough
    Foxborough, Massachusetts 02035, United States
    Recruiting
    • 877-DF-TRIAL · Contact877-338-7425
    • Sudha Bolla, MD · Principal investigator
  • Dana-Farber Cancer Institute Merrimack Valley
    Methuen, Massachusetts 01844, United States
    Recruiting
    • 877-DF-TRIAL · Contact877-338-7425
    • Ankur Mehta, MD · Principal investigator
  • Dana-Farber Brigham Cancer Center at Milford Regional Medical Center
    Milford, Massachusetts 01757, United States
    Recruiting
    • 877-DF-TRIAL · Contact8773387425
    • Natalie Sinclair, MD · Principal investigator
  • Dana-Farber Brigham Cancer Center at South Shore Health
    Weymouth, Massachusetts 02190, United States
    Recruiting
    • 877-DF-TRIAL · Contact8773387425
    • James Stoeckle, MD · Principal investigator
  • Dana-Farber/New Hampshire Oncology-Hematology
    Londonderry, New Hampshire 03053, United States
    Recruiting
    • 877-DF-TRIAL · Contact877-338-7425
    • Jeanna Walsh, MD · Principal investigator
  • Englewood Hospital
    Englewood, New Jersey 07631, United States
    Recruiting
  • Capital Health Medical Center - Hopewell
    Pennington, New Jersey 08534, United States
    Recruiting
  • Penn Medicine - Princeton Health
    Plainsboro, New Jersey 08536, United States
    Recruiting
  • Lovelace Medical Center - Saint Joseph Square
    Albuquerque, New Mexico 87102, United States
    Recruiting
    • Zemmie Pollock · ContactZPollock@salud.unm.edu · 505-727-3040
    • Bernard Tawfik, MD · Principal investigator
  • Lovelace Women's Hospital
    Albuquerque, New Mexico 87109, United States
    Recruiting
    • Zemmie Pollock · ContactZPollock@salud.unm.edu · 505-727-3040
    • Bernard Tawfik, MD · Principal investigator
  • Presbyterian Kaseman Hospital
    Albuquerque, New Mexico 87110, United States
    Recruiting
    • Monique Robertson · Contactmrobertso2@phs.org · 505-559-6100
    • Bernard Tawfik, MD · Principal investigator
  • The University of New Mexico Comprehensive Cancer Center
    Albuquerque, New Mexico 87131, United States
    Recruiting
  • Memorial Medical Center
    Las Cruces, New Mexico 88011, United States
    Recruiting
    • Deborah Brown · ContactDeborah.Brown@LPNT.net · 575-521-1554
    • Bernard Tawfik, MD · Principal investigator
  • Presbyterian Rust Medical Center/Jorgensen Cancer Center
    Rio Rancho, New Mexico 87124, United States
    Recruiting
    • Andrea Yost · Contactayost3@phs.org · 505-559-6100
    • Bernard Tawfik, MD · Principal investigator
  • Levine Cancer Institute
    Albemarle, North Carolina 28001, United States
    Recruiting
  • Levine Cancer Institute
    Charlotte, North Carolina 28204, United States
    Recruiting
  • Levine Cancer Institute
    Charlotte, North Carolina 28210, United States
    Recruiting
  • Levine Cancer Institute
    Charlotte, North Carolina 28211, United States
    Recruiting
  • Levine Cancer Institute
    Charlotte, North Carolina 28262, United States
    Recruiting
  • Levine Cancer Institute
    Charlotte, North Carolina 28277, United States
    Recruiting
  • Levine Cancer Institute
    Concord, North Carolina 28025, United States
    Recruiting
  • Levine Cancer Institute
    Forest City, North Carolina 28043, United States
    Recruiting
  • Levine Cancer Institute
    Gastonia, North Carolina 28054, United States
    Recruiting
  • Levine Cancer Institute
    Huntersville, North Carolina 28078, United States
    Recruiting
  • Levine Cancer Institute
    Lincolnton, North Carolina 28092, United States
    Recruiting
  • Levine Cancer Institute
    Matthews, North Carolina 28104, United States
    Recruiting
  • Levine Cancer Institute
    Monroe, North Carolina 28112, United States
    Recruiting
  • Levine Cancer Institute
    Shelby, North Carolina 28150, United States
    Recruiting
  • University of Cincinnati Medical Center
    Cincinnati, Ohio 45219, United States
    Recruiting
    • Bonny Lami · Contactlamiby@ucmail.uc.edu · 513-584-1239
    • Mahmoud Charif, MD · Principal investigator
  • University of Cincinnati Medical Center - West Chester Hospital
    West Chester, Ohio 45069, United States
    Recruiting
    • Bonny Lami · Contactlamiby@ucmail.uc.edu · 513-584-1239
    • Mahmoud Charif, MD · Principal investigator
  • Penn Medicine - Lancaster General Hospital
    Lancaster, Pennsylvania 17601, United States
    Recruiting
  • Capital Health Hematology Oncology Specialists
    Newton, Pennsylvania 18940, United States
    Recruiting
  • Penn Medicine - Perelman Center for Advanced Medicine
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
  • Penn Medicine - Pennsylvania Hospital
    Philidelphia, Pennsylvania 19106, United States
    Recruiting
  • Penn Medicine - Chester County Hospital
    West Chester, Pennsylvania 19380, United States
    Recruiting
  • Smilow Cancer Hospital - Westerly
    Westerly, Rhode Island 02891, United States
    Recruiting
    • Carl Brown · Contactcarl.brown@yale.edu · 475-241-1065
    • Maryam Lustberg, MD · Principal investigator
  • St. Joseph's Candler Bluffton Campus
    Bluffton, South Carolina 29910, United States
    Recruiting
    • Stephanie Reyes · Contactsmiths1@sjchs.org · 912-819-5723
    • Leonard Henry, MD · Principal investigator
  • SC Cancer Specialists - Hilton Head at St. Joseph's/Candler
    Hilton Head Island, South Carolina 29926, United States
    Recruiting
    • Stephanie Reyes · Contactsmiths1@sjchs.org · 9128195723
    • Leonard Henry, MD · Principal investigator
  • Levine Cancer Institute
    Rock Hill, South Carolina 29732, United States
    Recruiting
  • Baptist Memorial Healthcare
    Memphis, Tennessee 38120, United States
    Recruiting
  • Fred Hutchinson Cancer Center at Overlake Cancer Center
    Bellevue, Washington 98004, United States
    Recruiting
    • Jennifer Specht, MD · Contactjspecht@uw.edu · 206-606-6889
    • Jennifer Specht, MD · Principal investigator
  • Northwest Medical Specialties
    Bonney Lake, Washington 98391, United States
    Recruiting
  • Northwest Medical Specialties
    Federal Way, Washington 98003, United States
    Recruiting
  • Northwest Medical Specialties
    Gig Harbor, Washington 98332, United States
    Recruiting
  • Fred Hutchinson Cancer Center at EvergreenHealth
    Kirkland, Washington 98034, United States
    Recruiting
    • Jennifer Specht, MD · Contactjspecht@uw.edu · 206-606-6889
    • Jennifer Specht, MD · Principal investigator
  • Northwest Medical Specialties
    Olympia, Washington 98502, United States
    Recruiting
  • Northwest Medical Specialties
    Puyallup, Washington 98373, United States
    Recruiting
  • Fred Hutchinson Cancer Center
    Seattle, Washington 98109, United States
    Recruiting
    • Jennifer Specht, MD · Contactjspecht@uw.edu · 206-606-6889
    • Jennifer Specht, MD · Principal investigator
  • Fred Hutchinson Cancer Center at University of Washington-Northwest
    Seattle, Washington 98133, United States
    Recruiting
    • Jennifer Specht, MD · Contactjspecht@uw.edu · 206-606-6889
    • Jennifer Specht, MD · Principal investigator
  • Northwest Medical Specialties
    Tacoma, Washington 98405, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Aug 2028, 46 months after the start.

Of 328 non-industry phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 127. This study's planned 46 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2024
First posted
Apr 22, 2024
StartActual
Oct 29, 2024
Primary completionEst.
Aug 31, 2028
CompletionEst.
Sep 1, 2028
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
19 sites added
Show 19 added (19 United States)
  • Providence Medical Foundation · Eureka, United States
  • Providence Medical Foundation · Santa Rosa, United States
  • Liberty County Cancer Care · Hinesville, United States
  • Pembroke Medical Oncology & St Joseph's/Candler Oncology Infusion Suite · Pembroke, United States
  • Candler Medical Oncology Practice and Infusion · Statesboro, United States
  • Englewood Hospital · Englewood, United States
  • Capital Health Medical Center - Hopewell · Pennington, United States
  • University of Cincinnati Medical Center · Cincinnati, United States
  • University of Cincinnati Medical Center - West Chester Hospital · West Chester, United States
  • Capital Health Hematology Oncology Specialists · Newton, United States
  • Northwest Cancer Center · Crown Point, United States
  • Northwest Cancer Center-Dyer · Dyer, United States
  • St. Mary Medical Center · Hobart, United States
  • Powers Health Cancer Research Foundation · Munster, United States
  • Northwest Cancer Center · Valparaiso, United States
  • Fred Hutchinson Cancer Center at Overlake Cancer Center · Bellevue, United States
  • Fred Hutchinson Cancer Center at EvergreenHealth · Kirkland, United States
  • Fred Hutchinson Cancer Center · Seattle, United States
  • Fred Hutchinson Cancer Center at University of Washington-Northwest · Seattle, United States
across 3 updates, Sep 25, 2026 – Nov 2, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • Miami Cancer Institute · Plantation, United StatesContact K•••@baptisthealth.net · •••1566→d•••@baptisthealth.net · •••1494
  • Capital Health Medical Center - Hopewell · Pennington, United StatesContact D•••@capitalhealth.org · •••6014→T•••@capitalhealth.org · •••7042
  • Capital Health Hematology Oncology Specialists · Newton, United StatesContact D•••@capitalhealth.org · •••6014→T•••@capitalhealth.org · •••7042
across 2 updates, Sep 25, 2026 – Oct 6, 2026
Show all 3 updates
  1. Nov 2, 2026
    4 sites added
    Show 4 added (4 United States)
    • Fred Hutchinson Cancer Center at Overlake Cancer Center · Bellevue, United States
    • Fred Hutchinson Cancer Center at EvergreenHealth · Kirkland, United States
    • Fred Hutchinson Cancer Center · Seattle, United States
    • Fred Hutchinson Cancer Center at University of Washington-Northwest · Seattle, United States
  2. Oct 6, 2026
    5 sites added
    Show 5 added (5 United States)
    • Northwest Cancer Center · Crown Point, United States
    • Northwest Cancer Center-Dyer · Dyer, United States
    • St. Mary Medical Center · Hobart, United States
    • Powers Health Cancer Research Foundation · Munster, United States
    • Northwest Cancer Center · Valparaiso, United States
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Capital Health Medical Center - Hopewell · Pennington, United StatesContact D•••@capitalhealth.org · •••6014→T•••@capitalhealth.org · •••7042
    • Capital Health Hematology Oncology Specialists · Newton, United StatesContact D•••@capitalhealth.org · •••6014→T•••@capitalhealth.org · •••7042
    + 1 other change: verification date
  3. Sep 25, 2026
    10 sites added
    Show 10 added (10 United States)
    • Providence Medical Foundation · Eureka, United States
    • Providence Medical Foundation · Santa Rosa, United States
    • Liberty County Cancer Care · Hinesville, United States
    • Pembroke Medical Oncology & St Joseph's/Candler Oncology Infusion Suite · Pembroke, United States
    • Candler Medical Oncology Practice and Infusion · Statesboro, United States
    • Englewood Hospital · Englewood, United States
    • Capital Health Medical Center - Hopewell · Pennington, United States
    • University of Cincinnati Medical Center · Cincinnati, United States
    • University of Cincinnati Medical Center - West Chester Hospital · West Chester, United States
    • Capital Health Hematology Oncology Specialists · Newton, United States
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Miami Cancer Institute · Plantation, United StatesContact K•••@baptisthealth.net · •••1566→d•••@baptisthealth.net · •••1494

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06377852
Lead sponsor
American Society of Clinical Oncology
Collaborators
Patient-Centered Outcomes Research Institute
Responsible party
Sponsor
First posted
Apr 22, 2024
Start date
Oct 29, 2024
Primary completion
Aug 31, 2028 (estimated)
Completion
Sep 1, 2028 (estimated)
Last update
Nov 2, 2026

Study contacts

Jackie Perez, MPH
Contact
CDKstudy@asco.org
571-483-1300
Cindy MacInnis, MBA
Contact
CDKstudy@asco.org
Julie Gralow, MD
principal investigator · American Society of Clinical Oncology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Palbociclib · Ribociclib

Start the discussion